Buscar en
Radiología (English Edition)
Toda la web
Inicio Radiología (English Edition) Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia
Journal Information
Vol. 66. Issue S1.
Suplement “"Advances in Thoracic Radiology”
Pages S47-S56 (April 2024)
Share
Share
Download PDF
More article options
Visits
141
Vol. 66. Issue S1.
Suplement “"Advances in Thoracic Radiology”
Pages S47-S56 (April 2024)
Original articles
Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia
Alteraciones pulmonares persistentes tras 18 meses de neumonía por SARS-CoV-2
Visits
141
C. Valenzuelaa, L. de la Fuenteb, S. Hernándezb, M.J. Oliverab, C. Molinab, N. Montesc, C. Benavidesb, P. Caballerob,
Corresponding author
palomacsr@hotmail.com

Corresponding author.
a Servicio de Neumología, Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
b Servicio de Radiología, Hospital Universitario La Princesa. Universidad Autónoma de Madrid, Madrid, Spain
c Unidad de Apoyo Metodológico, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (8)
Show moreShow less
Tables (1)
Table 1. Clinical characteristics of 31 patients and HRCT findings at 18 months in 62 observations.
Special issue
This article is part of special issue:
Vol. 66. Issue S1

Suplement “"Advances in Thoracic Radiology”

More info
Abstract
Objective

To describe persistent pulmonary abnormalities detected on HRCT after 18 months of SARS-CoV-2 pneumonia, and to determine their extension and correlation with pulmonary function.

Patients and methods

A prospective cross-sectional study with an initial cohort of 90 patients in follow-up due to persisting lung abnormalities on imaging, functional respiratory impairment and/or respiratory symptoms. Of these, 31 (34%) were selected for analysis due to the persistence of their lung abnormalities on HRCT at 18 months after infection. A double reading was performed for each HRCT (62 observations).

Results

Of the 31 patients included: 20 (65%) were men; mean age was 67 years; 17 (55%) were smokers/ex-smokers. The mean hospitalisation time was 38 days. Eighteen (58%) patients were admitted to intensive care units. Five patients (16%) suffered an acute pulmonary thromboembolism and three (9.7%) had a pneumothorax. The mean time between the onset of pneumonia and the follow-up HRCT was 20.34 months. Nineteen percent of patients suffered from total lung function abnormalities; and ground-glass opacities and reticulation were present in 12% and 4.5% respectively. The findings of the 62 readings were: ground-glass opacities (100%), reticulation (83%), subpleural curvilinear lines (62%), parenchymal bands (34%), traction bronchiectasis (69%), displacement of vessels/fissures (46%) and honeycombing (4.9%).

Pulmonary function 18 months after the acute episode revealed a mean FVC of 92% of predicted value, with an FVC < 80% of predicted value in 11 patients (35.4%). Mean DLCO was 71% of predicted value, with a DLCO < 80% in 22 patients (70%).

We observed a statistically significant relationship between total lung function abnormalities on HRCT and FVC (P < 0.05), and a trend towards statistical significance with DLCO (P = 0.051); there was a statistically significant relationship between the presence of ground-glass opacities and FEV1/FVC (P < 0.01). The relationships between reticulation and FVC, FVC%, FEV1, FEV1% and DLCO% were also considered statistically significant (P < 0.05).

Conclusion

Persistent interstitial lung abnormalities are seen on HRCT for a subset of patients infected with SARS-CoV-2 pneumonia. Seventy percent of these patients suffered a slight decrease in DLCO.

Keywords:
SARS-CoV-2
COVID-19
Lung HRCT
Pulmonary sequelae
Post-COVID-fibrosis
Resumen
Objetivo

Describir después de 18 meses, de una neumonía por SARS-CoV-2, las alteraciones pulmonares persistentes en la TCAR, valorar la extensión de las lesiones y su relación con la función respiratoria.

Pacientes y método

Estudio transversal prospectivo de 90 pacientes en seguimiento por persistencia de alteraciones radiológicas, funcionales y/o síntomas respiratorios. Se seleccionaron 31 pacientes (34%) que mantenían alteraciones pulmonares en la TCAR a los 18 meses. Se realizó una doble lectura de las tomografías (62 observaciones).

Resultados

De los 31 pacientes: 20 eran hombres (65%), edad media 67 años; 17 pacientes (55%) eran exfumadores o fumadores; el tiempo medio de hospitalización fue de 38 días, necesidad de cuidados respiratorios intermedios en 18 pacientes (58%). Cinco pacientes (16%) tuvieron tromboembolismo pulmonar agudo, y tres neumotórax (9,7%). El tiempo medio desde la neumonía hasta la TCAR fue de 20,3 meses. La extensión de las alteraciones pulmonares totales, de las opacidades de vidrio deslustrado y de la reticulación fue del 19%, 12% y 4,5%, respectivamente. Los hallazgos de las 62 lecturas fueron vidrio deslustrado (100%), reticulación (83%), opacidades curvilíneas subpleurales (62%), bandas parenquimatosas (34%), bronquiectasias por tracción (69%), desplazamiento de vasos o cisuras (46%) y panalización (4,9%).

La situación funcional respiratoria a los 18 meses mostró una FVC media de 92% del valor predicho, con FVC menor del 80% del valor predicho en 11 pacientes (35,4%), y una DLCO media del 71% del valor predicho, con una DLCO menor del 80% en 22 pacientes (70% ).

Se observó relación significativa entre la extensión total de las alteraciones en la TCAR con la FVC (P < 0,05), con la DLCO hubo una tendencia a la relación significativa (P = 0,051); existió una relación significativa entre la extensión de las opacidades de vidrio deslustrado y FEV1/FVC (P<0,01). La extensión de la reticulación presentó asociación significativa (P < 0,05) con la FVC, la FVC%, la FEV1, la FEV1% y la DLCO%.

Conclusión

Un porcentaje de pacientes que han padecido neumonía por SARS-CoV-2 persisten con alteraciones intersticiales en la TCAR. El 70% mostró una disminución leve de la DLCO.

Palabras clave:
SARS-CoV-2
COVID-19
TCAR pulmonar
Secuelas pulmonares
Post-COVID-fibrosis

Article

These are the options to access the full texts of the publication Radiología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos